Group 1 - The company, Yidu Tech (02158), repurchased 378,600 shares at approximately HKD 6 per share on January 27, totaling nearly HKD 2.3 million, marking the second consecutive day of buybacks, with a cumulative total of 505,000 shares and over HKD 3 million in total repurchase amount [1] - The founder and chairman of the company, Gong Rujing, attended the 2026 Winter Davos Forum, engaging in high-level industry dialogues and meetings with global leaders from politics, business, and academia [1] - At the forum, a significant collaboration was announced involving Novartis Foundation, the Brunei Ministry of Health, and Yidu Tech's subsidiary EVYD, aimed at implementing a data-driven cardiovascular disease prevention project called CARDIO4Cities [1] Group 2 - The company has been recognized as the top performer in the "2025 Medical Big Data Company Rankings," marking its seventh consecutive year at the top, reflecting its strong technological foundation, mature product system, and extensive industry experience [1]

Group 1 - The company, Yidu Tech (02158), announced a share buyback plan, intending to repurchase approximately 378,600 shares at a cost of about HKD 2.27 million on January 27, 2026 [1]

Group 1 - The company, Yidu Tech (02158), announced a share buyback plan, spending approximately HKD 2.27 million to repurchase 378,600 shares on January 27, 2026 [1]

Group 1 - The company, Yidu Tech (02158.HK), announced a share buyback on January 27, spending HKD 2.27 million to repurchase 379,000 shares [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 醫渡科技有限公司 呈交日期： 2026年1月27日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02158 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | | 事件 | 已發行股份（不包括庫存 ...

Group 1 - The company, Yidu Tech (02158.HK), announced a share buyback on January 26, spending HKD 758,000 to repurchase 126,000 shares [1]

Group 1 - The company, Yidu Tech (02158), announced a share buyback plan, committing to repurchase 126,400 shares at a total cost of HKD 758,100 [1] - The buyback price per share ranges from HKD 5.99 to HKD 6.00 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 醫渡科技有限公司 呈交日期： 2026年1月26日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02158 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件 ...

Core Insights - The founder and chairwoman of the company participated in the World Economic Forum's 56th Annual Meeting, engaging in high-level discussions on the intelligent transformation of the healthcare industry and the role of AI in addressing global health challenges [1][3][5]. Group 1: AI and Healthcare Resilience - The company emphasized the importance of AI and big data in enhancing public health system resilience and addressing new health challenges driven by climate change [1]. - AI healthcare enterprises can leverage technology to monitor climate-sensitive disease trends and innovate chronic disease management, thereby improving societal health resilience [1]. Group 2: AI in Health Security - The company highlighted the critical role of AI in infectious disease monitoring, drug development, and health management during discussions on reconstructing health security [3]. - The use of federated learning and privacy computing technologies is being implemented to enhance data security while improving model training efficiency across regions [3]. Group 3: China's AI Healthcare Development - The company discussed China's unique advantages in AI healthcare, including rich application scenarios, an improving data ecosystem, and strong policy support [5]. - The global value of China's experience lies not only in technological breakthroughs but also in systematic implementation capabilities and efficient localization models [5]. Group 4: Global Collaboration and Innovation - The company is actively building and expanding its collaboration network through bilateral meetings with key stakeholders, including government officials and industry leaders [7]. - A significant partnership was announced with Novartis for a cardiovascular disease prevention project, showcasing the company's commitment to AI-driven healthcare solutions [7]. Group 5: Contribution to Global AI Healthcare Ecosystem - The company's presence at the forum underscored the role of new-generation Chinese tech entrepreneurs in contributing to global wisdom and fostering cross-sector collaboration for a resilient future [8].

Core Insights - Novartis, in collaboration with the Brunei Ministry of Health and EVYD, is launching the CARDIO4Cities project aimed at cardiovascular disease prevention and control using data and AI tools [1][6][9] Group 1: Project Overview - The CARDIO4Cities project will utilize the BruHealth digital health platform to identify high-risk populations and implement targeted interventions to reduce cardiovascular disease risks in Brunei [1][6] - This initiative is part of a broader strategy to transform public health systems from reactive to proactive management, leveraging real-world data for precise health management [6][9] Group 2: Health Statistics and Challenges - Cardiovascular diseases account for over 70% of global deaths, with Brunei facing significant pressure on its public health system due to these diseases being the leading cause of mortality [6][8] - Common challenges in addressing these diseases globally include outdated data infrastructure, fragmented information, and weak monitoring systems, which hinder effective health interventions [6] Group 3: Technological Innovation - The project will employ AI-driven risk stratification for cardiovascular diseases, allowing for differentiated management strategies based on risk levels [6][7] - EVYD's AI capabilities will enhance drug development processes for pharmaceutical companies, improving clinical trial efficiency and cost control [7] Group 4: BruHealth Platform - The BruHealth platform, initially developed for tracking infectious diseases during the pandemic, has evolved into a comprehensive digital infrastructure covering over 85% of Brunei's population [8] - The platform integrates government oversight, healthcare provider tools, and personal health services, becoming a core component of Brunei's health management system [8] Group 5: Global Implications - The collaboration not only offers a new solution for cardiovascular disease management in Brunei but also serves as a model for addressing non-communicable diseases globally [9] - As the project progresses, it is expected to enhance public health services in Brunei and reduce the health and social burdens associated with cardiovascular diseases [9]